MBRX - FDA Rare Pediatric tags for WP1066 lifts Moleculin Biotech

Moleculin Biotech (MBRX) soars 41% in premarket, after the FDA has designated Rare Pediatric Disease tag for its drug candidate WP1066, for each of three indications, including diffuse intrinsic pontine glioma, medulloblastoma and atypical teratoid rhabdoid tumor, all are types of brain tumor.Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.

For further details see:

FDA Rare Pediatric tags for WP1066 lifts Moleculin Biotech